COX-2、Ki-67与乳腺癌新辅助化疗疗效的关系

目的 研究COX-2、Ki-67在乳腺癌新辅助化疗前后的表达变化及其与新辅助化疗疗效的关系.方法 应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、Ki-67的表达.结果 新辅助化疗总有效率为70.8%,总临床获益率为95.8%.化疗前后COX-2阳性率、Ki-67指数变化显著,分别由化疗前的62.5%和(46.81±23.17)%,降到化疗后的41.7%和(33.23±18.11)%,P<0.05.化疗前后COX-2阳性的乳腺癌组织中Ki-67指数均显著高于COX-2阴性者,P<0.01.新辅助化疗后COX-2表达阳性者,化疗效果差(P<0.05);而Ki-67高表达者总有效率高于低表达者(P<0.05).结论 COX-2、Ki-67可作为指导乳腺癌新辅助化疗并预测化疗敏感性的分子生物学指标.

Correlation between expression of COX-2,Ki-67 and neoadjuvant chemotherapy in breast cancer

Objective To study the correlation between expression of COX-2,Ki-67 and neoadjuvant chemotherapy in breast cancer.Method COX-2 and Ki-67 were examined by immunohistochemical staining in 48 breast cancer samples.Results The overall response rate and clinical benefit rate to neoadjuvant chemotherapy were 70.8% and 95.8%,respectively.The expression of COX-2 and Ki-67 after the chemothempy [41.7% and (33.23±18.11)%] was significantly lower than those in prechemotherapy [62.5% and (46.81±23.17)%],P<0.05.Ki-67 index Was higher in COX-2 positive tumom than that in the COX-2 negative ones before and after neoadjuvant chemotherapy,P<0.01.The effect of neoadjuvant chemotherapy had a significantly negative correlation with COX-2 expression.Patients with high expression of Ki-67 were more likely to respond to treatment.Conclusion The expression of COX-2 and Ki-67 as molecular markers could be a guide for chemotherapy and prediction for neoadjuvant's response to chemotherapy in breast cancer.